All In Biotech

Drug Trial Radar · NCT07863115

TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization

Validation of the TRiP-cast Score and Evaluation of Adherence to Preventive Anticoagulant Treatment in Non-Hospitalized Patients With Lower Limb Trauma Requiring Immobilization

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Dec 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
University of MonastirAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, observational cohort study designed to externally validate the Trauma-Related Immobilization-related Prophylaxis (TRiP(cast)) score in Tunisian adults with acute lower-limb trauma requiring immobilization and managed as outpatients. The study will assess the ability of the TRiP(cast) score to identify patients at increased risk of symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. A secondary objective is to evaluate adherence to prescribed thromboprophylaxis and to compare adherence between patients receiving low-molecular-weight heparin (LMWH) and those receiving direct oral anticoagulants (DOACs). Factors associated with treatment adherence, bleeding events, and thromboembolic outcomes will also be investigated. Patients aged 18 years or older with acute lower-limb trauma requiring immobilization for at least 7 days will be enrolled consecutively and followed prospectively. The decision to prescribe thromboprophylaxis and the choice of anticoagulant will remain entirely at the discretion of the treating physician according to routine clinical practice. Study investigators will not influence treatment decisions. The results are expected to provide external validation of the TRiP(cast) score in the Tunisian population and improve risk stratification and thromboprophylaxis management in ambulatory patients with lower-limb trauma.

Conditions

  • Lower Extremity Injuries
  • Venous Thromboembolism (VTE)
  • Deep Vein Thrombosis
  • Pulmonary Embolism

Interventions

  • Low-Molecular-Weight Heparin (LMWH)Drug

    Low-molecular-weight heparin prescribed for venous thromboembolism prophylaxis according to the treating physician's routine clinical practice.

  • Direct Oral Anticoagulants (DOACs)Drug

    Direct oral anticoagulants prescribed for venous thromboembolism prophylaxis according to the treating physician's routine clinical practice.

  • No Thromboprophylaxis CohortOther

    No anticoagulant prophylaxis is prescribed as part of routine clinical care. Treatment decisions are made solely by the treating physician and are not influenced by the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of symptomatic venous thromboembolism (VTE)Time frame: Within 45 days after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Fattouma Bourguiba Monastir

    Monastir, Tunisia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.